Performance evaluation of a non-invasive one-step multiplex RT-qPCR assay for detection of SARS-CoV-2 direct from saliva.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
07 07 2022
Historique:
received: 09 03 2022
accepted: 27 06 2022
entrez: 7 7 2022
pubmed: 8 7 2022
medline: 12 7 2022
Statut: epublish

Résumé

Polymerase chain reaction (PCR) has proven to be the gold-standard for SARS-CoV-2 detection in clinical settings. The most common approaches rely on nasopharyngeal specimens obtained from swabs, followed by RNA extraction, reverse transcription and quantitative PCR. Although swab-based PCR is sensitive, swabbing is invasive and unpleasant to administer, reducing patient compliance for regular testing and resulting in an increased risk of improper sampling. To overcome these obstacles, we developed a non-invasive one-step RT-qPCR assay performed directly on saliva specimens. The University of Nottingham Asymptomatic Testing Service protocol simplifies sample collection and bypasses the need for RNA extraction, or additives, thus helping to encourage more regular testing and reducing processing time and costs. We have evaluated the assay against the performance criteria specified by the UK regulatory bodies and attained accreditation (BS EN ISO/IEC 17,025:2017) for SARS-CoV-2 diagnostic testing by the United Kingdom Accreditation Service. We observed a sensitivity of 1 viral copy per microlitre of saliva, and demonstrated a concordance of > 99.4% between our results and those of other accredited testing facilities. We concluded that saliva is a stable medium that allows for a highly precise, repeatable, and robust testing method.

Identifiants

pubmed: 35798820
doi: 10.1038/s41598-022-15616-6
pii: 10.1038/s41598-022-15616-6
pmc: PMC9261881
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11553

Subventions

Organisme : Medical Research Council
ID : MC_PC_20027
Pays : United Kingdom
Organisme : British Heart Foundation
ID : SP/15/9/31605
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/18/31/33759
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/14/59/31000
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/21/10545
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L012618/1
Pays : United Kingdom

Informations de copyright

© 2022. The Author(s).

Références

Sci Rep. 2021 Nov 4;11(1):21650
pubmed: 34737362
Cochrane Database Syst Rev. 2021 Mar 24;3:CD013705
pubmed: 33760236
Ann Intern Med. 2021 Jan;174(1):131-133
pubmed: 32857591
J Infect. 2020 Aug;81(2):e145-e147
pubmed: 32504740
Lancet Respir Med. 2021 Jun;9(6):562-564
pubmed: 33887248
Nat Med. 2021 Dec;27(12):2108-2110
pubmed: 34728830
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
JAMA Intern Med. 2021 Mar 1;181(3):353-360
pubmed: 33449069
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Otolaryngol Head Neck Surg. 2020 Sep;163(3):459-461
pubmed: 32450754
Int J Oral Sci. 2020 Feb 24;12(1):8
pubmed: 32094336
Eur J Pain. 2021 Apr;25(4):924-929
pubmed: 33394524
Nat Med. 2021 May;27(5):892-903
pubmed: 33767405
J Biosaf Biosecur. 2021 Jun;3(1):1-3
pubmed: 33521591
Methods Protoc. 2022 Mar 07;5(2):
pubmed: 35314662
Ann Intern Med. 2021 Apr;174(4):501-510
pubmed: 33428446
PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
Biomark Med. 2010 Feb;4(1):171-89
pubmed: 20387312
medRxiv. 2021 Dec 24;:
pubmed: 34988559
Med. 2021 Mar 12;2(3):263-280.e6
pubmed: 33521748
Front Med (Lausanne). 2020 Aug 04;7:465
pubmed: 32903849
Nat Microbiol. 2020 Oct;5(10):1299-1305
pubmed: 32651556
Sci Rep. 2021 Nov 22;11(1):22640
pubmed: 34811429
Cell. 2021 Sep 16;184(19):4848-4856
pubmed: 34480864

Auteurs

Harry H Jenkins (HH)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK. harry.jenkins1@nottingham.ac.uk.

Ana A Tellechea Lopez (AAT)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Francesco Saverio Tarantini (FS)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Hannah Tomlin (H)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Danielle Scales (D)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

I-Ning Lee (IN)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Siyu Wu (S)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Ralph Hyde (R)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Katarzyna Lis-Slimak (K)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Timothy Byaruhanga (T)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Jamie L Thompson (JL)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Sara Pijuan-Galito (S)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Lara Doolan (L)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Kazuyo Kaneko (K)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Penny Gwynne (P)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Caroline Reffin (C)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Emily Park (E)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Jayasree Dey (J)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Jack Hill (J)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Asta Arendt-Tranholm (A)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Amy Stroud (A)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Moira Petrie (M)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.

Chris Denning (C)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK. chris.denning@nottingham.ac.uk.

Andrew V Benest (AV)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK. andrew.benest@nottingham.ac.uk.

Claire Seedhouse (C)

School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK. claire.seedhouse@nottingham.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH